VivoSeq
Nephrology

Glomerulonephritis Rapidly Progressive

5

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Glomerulonephritis Rapidly Progressive is an early-stage landscape with 5 programs across 6 companies. The most active players are Alentis Therapeutics AG, Roche, AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Alentis Therapeutics AG

1 program

Phase 2Roche logo

Roche

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2E

Essen Biotech

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2M

Medeor Therapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive Glomerulonephritis
Recruiting·AAlentis Therapeutics AG·Phase 2·NCT06047171·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)